(51 days)
MicroScan® MICroSTREP plus® Panel
Not Found
No
The document describes a traditional broth dilution susceptibility test and an instrument for reading the results, but there is no mention of AI or ML in the description, performance studies, or key metrics. The instrument reading appears to be based on detecting growth inhibition, not complex pattern recognition or learning algorithms.
No
This device is designed to determine antimicrobial susceptibility, which is a diagnostic function, not a therapeutic one. It provides information to guide treatment but does not directly treat a condition.
Yes
Explanation: The device "determines quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci." This process identifies the effectiveness of antimicrobial agents against specific bacteria, which is a diagnostic function used to guide treatment decisions.
No
The device description explicitly mentions physical panels, broth, and incubation in a non-CO2 incubator or a MicroScan® WalkAway instrument, indicating it involves hardware components and not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "To determine bacterial antimicrobial agent susceptibility." This is a diagnostic purpose, specifically identifying how susceptible bacteria are to different antibiotics.
- Device Description: The device is a panel containing various antimicrobial agents used in a miniaturized broth dilution susceptibility test. This test is performed in vitro (outside the body) on a sample (bacterial colonies grown on solid media).
- Process: The process involves inoculating the panel with a standardized suspension of the organism, incubating it, and then reading the results to determine the minimum inhibitory concentration (MIC). This entire process is conducted in vitro.
The description clearly outlines a test performed on a biological sample (bacterial colonies) outside of the human body to provide diagnostic information about the sample's characteristics (antimicrobial susceptibility). This aligns directly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
To determine bacterial susceptibility to Trimethoprim/Sulfamethoxazole.
For determining antimicrobic susceptibility with Streptococcus pneumoniae.
The MicroScan MICroSTREP plus® Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35°C +/- 1°C in a non-CO2 incubator, and read visually according to the Package Insert. Additionally, the panels may be incubated in and read by a MicroScan® WalkAway instrument.
This particular submission is for the addition of instrument read capability of the antimicrobial Trimethoprim/Sulfamethoxazole, at concentrations of 0.06/1.15 to 8/152 mcg/ml on the MicroScan MICroSTREP plus® Panel.
The organisms which may be used for Trimethoprim/Sulfamethoxazole susceptibility testing on this panel are:
Streptococcus pneumoniae
Product codes (comma separated list FDA assigned to the subject device)
LRG, LTT
Device Description
The MicroScan MICroSTREP plus® Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35°C +/- 1°C in a non-CO2 incubator, and read according to the Package Insert.
The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test. Various antimicrobial agents are diluted in water, buffer or minute concentrations of broth to concentrations bridging the range of clinical interest. Panels are rehydrated with 115 µl Mueller-Hinton broth supplemented with 2-5% lysed horse blood (LHB) and buffered with 50 mM HEPES, after inoculation of the broth with a standardized suspension of the organism in saline. After incubation in a non-CO2 incubator for 20-24 hours, the minimum inhibitory concentration (MIC) for the test organism is manually read by observing the lowest antimicrobial concentration showing inhibition of growth. Additionally, the panels may be incubated in and read by a MicroScan® WalkAway instrument.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
The external evaluation was conducted with stock and CDC Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed instrument read method for the MICroSTREP plus® Panel by comparing its performance with Expected Results determined before the evaluation.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The proposed instrument read method for the MicroScan MICroSTREP plus® Panel demonstrated substantially equivalent performance with streptococcal isolates when compared with an expected result generated on a CLSI frozen Reference Panel, as defined in the FDA document "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", dated February 5, 2003.
The MICroSTREP plus® Panel demonstrated acceptable performance with an overall Essential Agreement of 100% for Trimethoprim/Sulfamethoxazole instrument read results compared with the Expected Result.
Instrument reproducibility testing demonstrated acceptable reproducibility and precision with Trimethoprim/ Sulfamethoxazole and the WalkAway® instrument.
Quality Control testing demonstrated acceptable results for Trimethoprim/Sulfamethoxazole.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement of 100%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
MicroScan® MICroSTREP plus® Panel
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
AUG 2 3 2005
510(k) Summary Information:
| Device Manufacturer: | Dade Behring Inc. |
|---|---|
| Contact name: | Maureen Mende, Regulatory Affairs Group Manager |
| Phone/Fax: | 916-374-3174/916-374-3144 |
| Date prepared: | June 26, 2006 |
| Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panel |
| Trade Name: | MicroScan MICroSTREP plus® Panel |
| Intended Use: | To determine bacterial susceptibility to |
| Trimethoprim/Sulfamethoxazole | |
| Indication for Use: | For determining antimicrobic susceptibility with |
| Streptococcus pneumoniae | |
| Predicate device: | MicroScan® MICroSTREP plus® Panel |
510(k) Summary:
The MicroScan MICroSTREP plus® Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35°C +/- 1°C in a non-CO2 incubator, and read according to the Package Insert.
The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test. Various antimicrobial agents are diluted in water, buffer or minute concentrations of broth to concentrations bridging the range of clinical interest. Panels are rehydrated with 115 µl Mueller-Hinton broth supplemented with 2-5% lysed horse blood (LHB) and buffered with 50 mM HEPES, after inoculation of the broth with a standardized suspension of the organism in saline. After incubation in a non-CO2 incubator for 20-24 hours, the minimum inhibitory concentration (MIC) for the test organism is manually read by observing the lowest antimicrobial concentration showing inhibition of growth. Additionally, the panels may be incubated in and read by a MicroScan® WalkAway instrument.
The proposed instrument read method for the MicroScan MICroSTREP plus® Panel demonstrated substantially equivalent performance with streptococcal isolates when compared with an expected result generated on a CLSI frozen Reference Panel, as defined in the FDA document "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", dated February 5, 2003.
This Premarket Notification (510[k]) presents data in support of reading the MICroSTREP plus Panel with Trimethoprim/Sulfamethoxazole on the MicroScan® WalkAway instrument.
The external evaluation was conducted with stock and CDC Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed instrument read method
1
for the MICroSTREP plus® Panel by comparing its performance with Expected Results determined before the evaluation. The MICroSTREP plus® Panel demonstrated acceptable performance with an overall Essential Agreement of 100% for Trimethoprim/Sulfamethoxazole instrument read results compared with the Expected Result.
Instrument reproducibility testing demonstrated acceptable reproducibility and precision with Trimethoprim/ Sulfamethoxazole and the WalkAway® instrument.
Quality Control testing demonstrated acceptable results for Trimethoprim/Sulfamethoxazole.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three wing-like shapes, symbolizing service to the nation. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the eagle.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
AUG 2 3 2006
Ms. Maureen Mende Regulatory Affairs Group Manager Dade Behring, Inc. 2040 Enterprise Boulevard West Scaramento, California 95691
Re: K061872
Trade/Device Name: MicroScan MICroSTREP plus® Panel Trimethoprim/Sulfamethoxazole (0.06/1.15 - 8/152 mcg/ml) Regulation Number: 21 CFR & 866.1640 Regulation Name: Antimicrobial susceptibility test powder Regulatory Class: II Product Code: LRG, LTT Dated: June 28, 2006 Received: July 19, 2006
Dear Ms. Mende:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97), Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally, artton
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indication for Use Statement
| 510(k) No.: | K061872
(To be assigned by FDA) |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device Name: | MicroScan MICroSTREP plus ® Panel
Trimethoprim/Sulfamethoxazole (0.06/1.15 - 8/152 mcg/ml) |
| Intended Use | To determine bacterial antimicrobial agent susceptibility |
| Indications for Use: | The MicroScan MICroSTREP plus ® Panel is used to determine
quantitative and/or qualitative antimicrobial agent susceptibility of
colonies grown on solid media of aerobic streptococci, including
Streptococcus pneumoniae . After inoculation, panels are incubated
for 20 - 24 hours at 35°C +/- 1°C in a non-CO2 incubator, and
read visually according to the Package Insert. Additionally, the
panels may be incubated in and read by a MicroScan ® WalkAway
instrument. |
This particular submission is for the addition of instrument read capability of the antimicrobial Trimethoprim/Sulfamethoxazole, at concentrations of 0.06/1.15 to 8/152 mcg/ml on the MicroScan MICroSTREP plus® Panel.
The organisms which may be used for Trimethoprim/Sulfamethoxazole susceptibility testing on this panel are:
Streptococcus pneumoniae
| Prescription Use
| (Per 21 CFR 801.109) | OR | Over-The-Counter Use ________ |
|---|---|---|
| ------------------------------------------------------------------------ | ---- | ------------------------------- |
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Sall
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) $\frac{K_{0}6(87)}{}$
viii